Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation by Schwaak, A. J. G. et al.
PAPER
Systemic lupus erythematosus. Disease outcome in patients with
a disease duration of at least 10 years: second evaluation{
AJG Swaak1*, HG van den Brink2, RJT Smeenk2, K Manger3, JR Kalden3, S Tosi4, Z Domljan5, B Rozman6, D Logar6,
G Pokorny7, L Kovacs7, A Kovacs8, PG Vlachoyiannopoulos9, HM Moutsopoulos9, H Chwalinska-Sadowska10, E Kiss11,
N Cikes12, B Anic12, M Schneider13, R Fischer13, S Bombardieri14, M Mosca14, W Graninger15 and JS Smolen15 (Members
of the study group subclinical SLE and SLE with a disease duration longer than 10 years)
1Department of Rheumatology, Medisch Centrum Rijnmond Zuid, Rotterdam, The Netherlands; 2Department of Auto-immune Diseases, Central
Laboratory Blood Transfusion Service, Amsterdam, The Netherlands; 3Department of Internal Medicine III and Institute for Clinical Immunology,
University Erlangen-Nurnberg, Erlangen, Germany; 4Rheumatology Unit, Istituto Ortopedico Gaetano Pini, Milano, Italy; 5Department of Rheumatology
and Rehabilitation, University Hospital Zagreb, Zagreb, Croatia; 6Department of Rheumatology, Dr Peter Drzaj Hospital, Ljubljana, Slovenia; 7First
Department of Internal Medicine, Dr A. Szent-Gyorgyi Medical University Centre, Szeged, Hungary; 8Blood Transfusion Institute, Dr A. Szent-Gyorgyi
Medical University Centre, Szeged, Hungary; 9Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece;
10Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland; 11Department of Internal Medicine, Medical University of
Debrecen, Debrecen, Hungary; 12Division of Clinical Immunology and Rheumatology, Department of Medicine, University Hospital Center, Zagreb,
Croatia; 13Medical Clinic, Department of Rheumatology, Heinrich-Heine University, Dusseldorf, Germany; 14Universita degli Studi di Pisa, Dipartimenti
di Medicina Interna, Italy; and 15Department of Rheumatology, University of Vienna, Vienna, Austria
Data related to the disease course of patients with systemic lupus erythematosus (SLE) with special
attention to the persistence of disease activity in the long term are scarce. At this moment reliable
figures are only known about the survival rate as a measure of outcome. The aim of this multicenter
study was to describe the outcome of SLE patients with a disease duration of greater than 10 y.
Outcome parameters were two disease activity-scoring systems (SLEDAI and ECLAM), the end
organ damage (SLICC=ACR damage index) and treatment. Our results are derived from 187 SLE
patients followed at 10 different centres in Europe over a period of 1 y. Serious clinical signs or
exacerbations, defined by the occurrence or detoriation of already existing symptoms of renal and
cerebral nervous systems were observed in 2 – 11% of the patients, seizures and psychosis in 3%,
proteinuria in 11% and an increase in serum creatinine in 5% of the patients. No change took place
in the overall damage index. Yet, the disease course in most patients was characterized by periods
of tiredness (42 – 60%), arthritis (20 – 25%), skin involvement such as malar rash (32 – 40%),
migraine (15 – 20%), anaemia (15%) and leucopenia (17 – 19%). Summarizing these results it is
shown that patients, still under care after such a long time of having this disease, do have a disease
that is far from extinguished. Lupus (2001) 10, 51–58.
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Introduction
The survival of patients with systemic lupus erythe-
matosus (SLE) has improved dramatically from a 5 y
survival of 50% in 1950, to a 90% 10 y survival in the
1990s, while the 20 y survival figures approach
70%.1 – 5 These figures are derived from patients
with a Caucasian descent. Significantly poorer survi-
val rates are found in black Caribbean6 and Indian
SLE patients.7
The improved survival rates may be related to the
advanced medical therapy in general (antihyperten-
sive agents, availability of renal dialysis, transplanta-
tion and antibiotics), along with a better understanding
of the pathogenesis of the disease, earlier diagnosis
and inclusion of milder cases in recent studies, but it
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may also be caused by the more intensive forms of
treatment such as the use of cytotoxic drugs, immu-
nosuppressive drugs and high-dose prednisolone.
On the other hand, Albert8 noticed that survival, as
well as average disease duration, had increased in a
linear fashion, with no apparent change in the slope of
the curve since the mid 1950s, when first high-dose
steroid treatment and later immunosuppressive and
cytotoxic drugs, respectively, were widely introduced.
In the past attention in the literature has been
focused on survival and on the possible factors that
may have an influence on the outcome. Only a few
reports have discussed the fact that the disease course
is characterised by fluctuations in disease activity and
that SLE patients may have long periods in which the
disease is not active (remission).9 – 11
Neither the frequency, recurrence and duration of
remissions, nor the factors that may influence their
occurrence nor the characteristics of patients in whom
remissions are more likely to occur, have been deter-
mined. In a recent study12 it was observed that
treatment-free remissions could be achieved in
nearly a quarter of patients with SLE and that about
half of these patients remained in their first remission
for a mean period of almost 6 y. However, in this
study indices of disease activity were not used. At the
moment limited data are available about disease
activity of SLE patients when they have survived
the first 5 – 10 y of their disease. For the outcome,
not only the survival rate is important, but also the
eventual end-organ damage as well as the disease
activity present at such a time. At the moment the end-
organ damage and disease activity can be described by
a number of validated scoring systems such as the
SLE Activity Index (SLEDAI),13 the European Con-
sensus Lupus Activity Measure (ECLAM)14 and the
Systemic Lupus International Collaborative Clinics=
American College of Rheumatology Damage Index
(SLICC=ACR)15 for the assessment of accumulated
damage.
To obtain more insight into the disease course more
than 10 y after disease onset, an international study
was started under supervision of the EULAR Standing
Committee of International Clinical Studies Including
Therapeutic Trials (ESCISIT) in 1994. The aim of this
study was to describe the disease course after duration
of 10 or more years, with special attention on the
existing disease activity, the eventual changes in
disease activity during follow-up and the end-organ
damage.
In the first evaluation report16 the outcome para-
meters SLEDAI, ECLAM and the SLICC=ACR
showed that SLE patients who survived 10 y after
disease onset still showed some disease activity,
mostly related to symptoms derived from the skin
and musculoskeletal systems followed by renal invol-
vement. However, 72% of the patients still needed
treatment with prednisolone (7.5 mg=day). In 1994
a total of 187 SLE patients were included, and these
patients were followed for 1 y after inclusion, with the
intention of analysing clinical data related to the
different disease activity scoring systems and damage
indices according to a defined protocol (1994). Also
clinical signs related to SLE were noted in 1995 which
had changed in that year (interval 1994 – 1995), as well
as treatment and end organ damage.
Materials and methods
Ten different centres of rheumatology in Europe
participated in the co-operative study. In total, 187
SLE patients were included. All SLE patients who
fulfilled the revised ARA classification criteria,17 who
were known to the collaborating centres and who had
been followed for at least 10 y participated in the
study.
The inclusion of all patients took place during the
last 3 months of 1994. From that time the patients
were followed with special attention to changes in the
disease course. All protocols per patient were gathered
yearly at the end of the year. Demographic features of
all 187 SLE patients are shown in Tables 1 and 2. In
all participating centres, all consecutive patients were
included who were seen during that time period and
had a disease duration of at least 10 y. Of every centre
the protocols were gathered at the end of each
following year. The second evaluation took place 12
months after inclusion.
The clinical data of the patients were registered in
database protocols, with special attention to the dis-
ease course in the past, the disease activity present at
the time of inclusion and the extent of organ damage.
Table 1 Demographic data of 187 SLE patients with a disease
duration longer than 10 y
AVG STD
Age at onset 29 12
Age at diagnosis 31 12
Age at protocol 46 12
Female:male 166:21
Table 2 Geographical distribution
Number of patients Percentage
Western Europe 55 29
Central Europe 57 30
Southern Europe 41 22
Eastern Europe 34 18
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A standardised history chart containing relevant clin-
ical signs for the time of onset and diagnosis (defined
by the moment of fulfilling the 1982 ARA criteria)
was filled in. These data were obtained using the
patient’s medical charts. For obtaining an impression
of disease activity at entry, the SLE disease activity
index (SLEDAI)13 and European Consensus Lupus
Activity Measure (ECLAM)14 were used. Also, a
global damage index (DI), describing the total sum
of all the damage that has occurred by using the
definitions of clinical features SLICC=ACR was
calculated.15
In order to standardise the data entries; every item
in the protocols was defined according to the Dic-
tionary of the Rheumatic Disease prepared by the
Glossary Committee of the American College of
Rheumatology.18 Otherwise, definitions were based
on the most commonly used textbooks of internal
medicine or rheumatology.
The clinical manifestations were defined as fol-
lows:
1. Malar (butterfly) rash — fixed erythema, flat or
raised, over the malar eminences, tending to spare
the nasolabial folds.
2. Discoid lesions — erythematous raised patches
with adherent keratotic scaling and follicular
plugging.
3. Subacute cutaneous lesions — photosensitive,
non-scarring dermatitis appearing as either papu-
losquamous (psoriatiform) or annular lesions.
4. Photosensitivity — skin rash as a result of unusual
reaction to sunlight, documented by patient his-
tory or physician observation.
5. Oral ulcers — oral or nasopharyngeal ulceration,
usually painless, observed by physician.
6. Arthritis — non-erosive arthritis involving two or
more peripheral joints characterized by tender-
ness, swelling or effusion.
7. Serositis — (a) pleuritis (convincing history of
pleuritic pain or rub or evidence of pleural effu-
sion) or (b) pericarditis (documented by electro-
cardiogram, rub or evidence of pericardial
effusion).
8. Nephropathy — (a) persistent proteinuria > 0.5 g=
day or> 3 if quantitation was not performed, or
(b) cellular casts (may be red cell, haemoglobin,
granular, tubular or mixed), or (c) otherwise
unexplained elevation of serum creatinine
> 75mmol=l.
9. Neurologic involvement — (a) seizures in the
absence of offending drugs or known metabolic
derangements, eg uraemia, ketoacidosis or elec-
trolyte imbalance, or (b) psychosis in the absence
of offending drugs or known metabolic derange-
ments, eg uraemia, ketoacidosis or electrolyte
imbalance.
10. Thrombocytopenia — < 100 000=mm3 in the
absence of offending drugs.
11. Haemolytic anaemia — decrease of  30 g=l in
the blood haemoglobin, coincident with a rise in
conjugated bilirubin of  10.3mmol=l and a reti-
culocyte count > 5% at the time of the haemo-
lytic episode.
12. Fever — temperature of > 38C or 100F in the
absence of an infection.
13. Raynaud phenomenon — blanching of the fingers,
toes, ears, nose, tongue, induced by exposure to
cold, stress or both.
14. Livedo reticularis — reddish or cyanotic disco-
loration of the skin with a reticular pattern.
15. Thrombosis — venous and=or arterial thrombosis
diagnosed on clinical grounds and confirmed by
complementary tests.
16. Myositis — muscle weakness accompanied by
elevation of muscle enzymes, and electromyo-
graphic or biopsy findings characteristic of myo-
sitis.
17. Lung involvement — (a) acute lupus pneumonitis
(fever, cough, pulmonary infiltrates on X-ray in
the absence of an infection (pathogens that cannot
be cultured or isolated)), or (b) chronic lupus
pneumonitis (diffuse interstitial infiltrates on
X-ray with a restrictive pattern on pulmonary
function studies); pulmonary oedema, adult
respiratory distress syndrome, infectious pneu-
monia, malignancy and granulomatous disease
must be excluded.
18. Chorea — rapid, involuntary, purposeless and
variable movements.
19. Sicca syndrome — keratoconjunctivitis sicca con-
firmed by a positive Schirmer test and character-
istic Rose Bengal staining, and xerostomia
confirmed by sialometry, typical changes in sali-
vary scintigraphy or positive labial biopsy.
20. Lymphadenopathy — enlarged nodes (> 0.5 cm)
in the cervical region, axial, or inguinal area in
the absence of infection or malignancy.
Cumulative damage
The presence of irreversible structural or functional
change in a variety of organ systems was recorded
with the Systemic Lupus International Co-operating
Clinics=ACR Damage Index (DI).15 For inclusion the
damage had to have occurred since diagnosis of SLE
and had to be present for at least 6 months. The
clinical records were screened for changes in clinical
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signs related to ocular-, neuropsychiatric-, renal-,
pulmonary-, cardiovascular-, peripheral vascular-,
gastrointestinal- and musculoskeletal systems, the
presence of skin disease, ovarian failure, diabetes,
malignancy, obesity and osteoporosis. Hypertension
was included because it was observed to be the most
significant risk factor for mortality in SLE, much
more so than the more specific measures of disease
severity.22 The SLICC=ACR damage index was
divided into two parts, the first part containing all
parameters related to the validated SLICC=ACR
damage index with the exclusion of diabetes, and
hypertension was included. The second part contained
clinical signs related overall to complications of
treatment and defined as comorbidities, such as:
Cushing phenomenon, gastro-intestinal bleeding, obe-
sity and other drug-related adverse events. One year
after inclusion in the study of every patient, in the
same month as the patient was registered, a second
investigation took place. In this investigation attention
was paid to the existing disease activity, clinical signs
(which may have taken place in the previous year),
eventual change in the damage index and treatment.
Results
Disease activity 1 y after inclusion in the study as defined
by the SLEDAI and ECLAM scoring systems.
As shown in Table 3, no difference could be calcu-
lated between the disease activity measured in 1994
and that in 1995, by comparing the different disease
scoring systems. However one should realize that the
overall disease activity remains the same, but in the
individual patients a defined clinical sign could dis-
appear, remain present, increase in severity or become
manifest.
Damage index 1 y after inclusion in the study as defined by
the SLICC=ACR damage index
The results of the damage indices as recorded in 1995
are shown in Table 3. No significant difference was
calculated in the total scores between 1994 and 1995.
From the results it can be concluded that for the whole
group of SLE patients no significant changes in the
disease course took place in the time interval from
1994 to 1995.
Changes in clinical signs of patients with systemic lupus
erythematosus between 1994 and 1995
As shown before, no changes took place overall in the
disease activity scores for the whole group of patients
in these two periods. According to the design of the
protocol the clinical activity was scored using a
combined scoring list containing clinical signs defined
by the SLEDAI and ECLAM index forms. In 1995 the
presence of the defined symptom was compared with
that in 1994. In this way an impression can be
obtained of the changes between these two periods
in disease activity, not only for all patients taken
together, but also for the individual patient. Different
possibilities could be considered at the time the
protocols were filled in: the clinical sign could be
present or not; when present the clinical sign could be
Table 3 The change in the disease course during follow-up of
SLE patients with a disease duration longer than 10 y
1994 1995
AVG STD AVG STD
Disease activity scoring systems
SLEDAI 7.5 9.6 7.6 9.3
ECLAM 5.3 5.0 4.2 3.7
Damage index
 co-morbiditya 3.7 4.3 3.1 4
7 co-morbiditya 2.8 3.4 2.5 3.4
aCo-morbidity was related to symptoms such as Cushingoid appearances,
diabetes, infection, malignancy, pulmonary embolus, gastro-intestinal
bleeding, obesity and drugs.
Table 4 The course of the general disease manifestations, skin
and musculoskeletal symptoms in 187 SLE patients with disease
duration > 10 y, in the time interval 1994 – 1995
Percentage of patients
Not present or ameliorated Present or worsened
Clinical sign 1 2 3 4 5 6
Fever 84 3 0 2 10 1
Tiredness 37 20 1 21 3 18
Arthritis 68 5 2 10 12 3
Arthralgia 33 13 2 30 19 3
Malar rash 55 4 1 26 13 1
Generalized rash 92 2 1 0 4 1
Discoid rash 93 3 0 2 2 0
Skin vasculitis 84 4 0 2 9 1
Oral ulcer 94 1 0 1 4 0
1 — Percentage of patients in whom the defined clinical signs were not
observed during follow-up.
2 — Percentage of patients in whom in 1995 the defined clinical sign had
disappeared.
3 — Percentage of patients in whom in 1995 the defined clinical sign had
ameliorated.
4 — Percentage of patients in whom in 1995 the defined clinical sign was
present and unchanged with regard to 1994.
5 — Percentage of patients in whom the defined clinical sign was observed
in 1995 for the first time.
6 — Percentage of patients in whom the defined clinical sign worsened in
1995.
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recorded as present and unchanged or increased in
severity, or had totally disappeared or was overall not
present in the preceding period.
In Table 4 the percentage of patients is depicted in
relation to the presence or absence of a particular
defined clinical activity, related to general disease
manifestations, skin and musculoskeletal system. It
is shown that, when disease activity is scored at two
points in time, in up to 42% of the patients a particular
symptom can vary in time. Tiredness showed the most
variation (42%) followed by arthralgia (37%), arthritis
(22%), malar rash (19%) and skin vasculitis (14%). Of
symptoms present in 1995 the most frequent were
tiredness, arthralgia and malar rash, in 43, 52 and 40%
of the cases respectively. Pericarditis was present in
4% of the patients, while at the time of evaluation this
symptom was aggravated in 2%, the same as for
myositis.
Intestinal manifestations like intestinal vasculitis
were diagnosed in 3% of the patients, disappeared in
1% and worsened in 2%. However, in 2% a sterile
pneumonitis was seen for the first time.
In Table 5 the course of clinical signs related to the
central nervous system and renal involvement are
shown. Migraine was the most frequent symptom
that showed a tendency to change. Amelioration or
worsening took place in 22% of the patients. With
regard to renal involvement various symptoms chan-
ged significantly in time, eg proteinuria in 17%,
urinary casts in 11% and haematuria in 14% of the
patients. In the time interval 1994 – 1995 anaemia was
observed in 15% of the patients, while this symptom
subsided or ameliorated in 9%, stayed stable in 5%,
was observed as a new symptom in 9% and worsened
in 1% of the patients. Of the haematological signs
leucopenia had the highest prevalence and showed the
greatest variation in severity: it ameliorated in 9% and
worsened in 13% of the patients (Table 6).
Changes in disease activity have been summarized
in Table 7. In this table the prevalence of clinical signs
in relation to the overall change in their frequencies is
shown. In this way, the most frequently observed
symptoms, having a great tendency to change in
time, were arthralgia (52% vs 22%; presence vs
change in frequency), malar rash (40% vs 4%), tired-
ness (60% vs 21%), arthritis (25% vs 15%) and more
serious signs like proteinuria (22% vs 11%).
Changes in treatment of patients with systemic lupus
erythematosus between 1994 and 1995
That the disease course in the investigated patients is
still not stable is illustrated by the changes in treat-
ment modalities, next to the fact that quite a few
patients are still treated with prednisolone (73%),
azathioprine (20%) and cyclophosphamide (7%)
(Table 8). In 1994 72% of the patients were treated
with prednisolone, and in 1995 73%. For azathioprine
the figures were 15% in 1994 and 20% in 1995. These
data illustrate that, for different forms of treatment, in
quite a number of patients the regimen was changed,
Table 5 The course of the neuropsychiatric and renal clinical
signs in 187 SLE patients with disease duration > 10 y, in the time
interval 1994 – 1995
Percentage of patients
Not present or ameliorated Present or worsened
Clinical sign 1 2 3 4 5 6
Migraine 72 13 0 6 8 1
Seizures 95 2 0 0 2 1
Stroke 95 2 0 1 2 0
Organic brain damage 93 2 1 0 4 0
Psychosis 93 3 0 1 2 1
Proteinuria 72 5 1 11 8 3
Urinary casts 83 5 1 6 3 2
Haematuria 81 2 1 5 9 2
Raised serum creatinine 84 4 0 7 4 1
1 — Percentage of patients in whom the defined clinical signs were not
observed during follow-up.
2 — Percentage of patients in whom in 1995 the defined clinical sign had
disappeared.
3 — Percentage of patients in whom in 1995 the defined clinical sign had
ameliorated.
4 — Percentage of patients in whom in 1995 the defined clinical sign was
present and unchanged in regard to 1994.
5 — Percentage of patients in whom the defined clinical sign was observed
in 1995 for the first time.
6 — Percentage of patients in whom the defined clinical sign worsened in
1995.
Table 6 The course of the haematological manifestations in 187




Clinical sign 1 2 3 4 5 6
Anaemia 76 8 1 5 9 1
Leukopenia 72 8 1 6 11 2
Thrombocytopenia 89 4 0 2 5 0
Lymphocytopenia 73 10 0 6 9 2
1 — Percentage of patients in whom the defined clinical signs were not
observed during follow-up.
2 — Percentage of patients in whom in 1995 the defined clinical sign had
disappeared.
3 — Percentage of patients in whom in 1995 the defined clinical sign had
ameliorated.
4 — Percentage of patients in whom in 1995 the defined clinical sign was
present and unchanged in regard to 1994.
5 — Percentage of patients in whom the defined clinical sign was observed
in 1995 for the first time.
6 — Percentage of patients in whom the defined clinical sign worsened in
1995.
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varying for example for NSAIDs vs cyclosporine from
17% to 2%.
Discussion
An important problem common to chronic diseases is
how to estimate the prognosis of an individual patient.
Figures obtained from a large group of patients are
difficult to apply to an individual patient. In the past
three decades the general concept of the disease
course of SLE has changed dramatically. A new one
in which remission occurs with improving survival
rates has replaced the old view of a relatively unre-
mitting disease course ending with death in a few
years. In the past, most attention was paid to the
survival rate as outcome measure, and the impact of
age,20,21 sex,22,23 race,23 socio-economic status24 and
organ failure25 was investigated on the outcome. The
reported improvement was claimed to be the result of
more judicious use of immunosuppressive medica-
tions, and the availability of better treatments for
organ damage, particularly in end-stage renal disease.
At this moment, data about the long-term disease
course are limited. In the past, different studies
reported the occurrence of remissions. Dubois
described remissions of the disease in 1956 to occur
in 35% of 520 patients; some of the remissions lasted
for 10 – 20 y.26 In a recent study,12 these figures were
confirmed, showing a continuous increase in the like-
lihood of having a remission of the disease from onset
up to 20 y later, when 50% had reached remission.
However, for estimating prognosis not only these two
end-points in the disease (death (survival) rate vs
remission) are important, but also issues related to
persisting disease activity and possible end-organ
damage (end-stage renal disease).
In order to find answers to these questions, an
international study was started under the supervision
of the EULAR Standing Committee on International
Clinical Studies, in 1994. The aim of this study was to
describe the disease course in a cohort of SLE patients
with a long disease duration ( 10 y) obtained from
different centres in Europe, with special attention to
the existing disease activity, the incidence of flare ups,
aspects of ongoing treatment and the extent of end-
stage organ damage. It should be stressed that our
results were obtained from 10 different centres. Bias
might be caused by ethnic differences, or differences
in treatment modalities, socio-economic status, health
service and other factors. However, by dividing our
patients into different geographic cohorts, no differ-
ences between the different groups could be deter-
mined.16 The first results show that SLE patients who
survived 10 y or more after disease onset still showed
a significant disease activity, mostly related to clinical
signs of the skin and musculoskeletal system and to
the presence of renal involvement. To our surprise,
however, 72% of the patients still needed treatment
with prednisolone ( 7.5 mg). The cumulative
damage was related overall to clinical features derived
by damage of the central nervous system and renal
involvement, next to deforming arthritis, osteoporosis
and hypertension.16
In 1994 187 SLE patients were included in this
international study and were followed with the inten-
tion of analysing the eventual change in disease
activity and damage index 1 y after inclusion. Accord-
Table 8 Percentage of patients treated with the defined drug, and
the percentage of patients in whom the treatment was changed in
the time interval 1994 – 1995
Percentage of patients




Treatment Not treated Stopped Total Started Continued Total
NSAIDs 77 5 82 12 6 18
Prednisolone 21 6 27 8 65 73
Antimalarials 83 4 87 7 6 13
Azathioprine 77 3 80 8 12 20
Cyclophosphamide 92 1 93 3 4 7
Cyclosporine A 98 1 99 0 1 1
Table 7 The prevalence of the different clinical signs in 1994
and 1995
Percentage of patients Occurrence
and=or
Clinical signs 1994 1995 deterioration
General Fever 6 13 11
manifestations Tiredness 60 42 21
Articular Arthritis 20 25 15
manifestations Arthralgia 48 52 22
Skin Malar rash 32 40 14
manifestations Generalized rash 4 5 5
Neuropsychiatric Migraine 20 15 9
manifestations Seizures 3 3 3




Psychosis 5 4 3
Renal Proteinuria 20 22 11
manifestations Urinary casts 18 11 5
Haematuria 10 16 11
Raised serum 12 12 5
creatinine
Haematology Anaemia 15 15 10
Leukopenia 17 19 13
Thrombopenia 6 7 5
Lymphopenia 18 17 11
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ing to the results, it can be concluded that for the
whole group no changes took place in the disease
course and that no significant differences could be
calculated in the two disease activity scoring systems
and damage index when the results of 1994 and 1995
were compared. According to this finding it can be
concluded that after 10 or more years the patients will
still show signs of disease activity related to SLE. In
this regard it is very important to note that the scoring
systems (SLEDAI, ECLAM and SLICC=ACR DI)
which are used in this study are validated and
shown to be reliable by both experienced and non-
experienced observers.27 – 29 Yet more importantly, the
scoring systems were also shown to be sensitive to
changes in disease activity over time.30 Recently, the
reliabilities of the SLICC=ACR DI and SLEDAI were
confirmed and validated in an international study.31,32
In this study it was clearly shown that physicians
from different centres are able to assess patients with
SLE in a reproducible way with respect to disease
activity and SLICC=ACR DI. All the reported studies
also showed that these scoring systems could be used
in clinical research involving multiple centres. Using
these validated scoring systems our study clearly
shows that after 10 y of having SLE only a small
part (27%) of the patients may be considered to have a
remission, defined by absence of use of corticosteroids
and=or immunosuppressive drugs.12 At this moment
no prospective studies are known which present data
of a cohort of SLE patients showing the percentage of
SLE patients entering a remission (defined by with-
drawal of corticosteroids and=or immunosuppressive
drugs). Although we found that 27% of the patients
fulfilled the criteria for a remission-free period, nearly
all of the patients still showed clinical signs related to
the disease. That the disease is going on is best
illustrated in Table 7, showing that the clinical signs
with the highest prevalence also demonstrated the
greatest changes in time (eg tiredness, arthralgia,
arthritis, malar rash, migraine and leucopenia).
However, when flare-ups are defined by an increase
of disease activity or when they are observed as a new
clinical symptom in the time interval 1994 – 1995, a
significant number of our patients (3 – 11%) had an
exacerbation of their disease. Seizures were noticed
for the first time in 2% and to be increased in 1% of
the patients, stroke was observed in 2% for the first
time, psychosis in 2% and increased in 1%. Exacer-
bations related to the renal system were noted in 11%
of the patients, with 8% developing a proteinuria
while in 3% an increase in proteinuria was noted. A
deterioration in the creatinine clearance (CC) was
noted in 5% of the patients, 4% demonstrated a
deterioration in the CC for the first time and 1% a
further decrease. These results show that a large
proportion of these SLE patients do not demonstrate
extinction of the disease, but rather still active disease
with an exacerbation rate of approximately 11 per 100
patients per year (21 exacerbations in 187 patients=y).
Furthermore, a number of our patients showed symp-
toms of activity of the musculoskeletal system, skin
and periods of tiredness and fever.
This study will not give an answer to the question
of how many patients will enter into remission of
their disease. This is caused by our selection proce-
dure: the patients were still followed at the different
centres, and in that sense may still need some kind of
treatment. Patients that had entered a remission in the
past may be lost to our investigation caused by the
fact that no treatment is needed. It should therefore
be stressed that our data are only applicable to
patients who are still under our care. Considering
this fact the conclusion can be made that after 10 y
the disease is still not extinguished. However, as
illustrated in Table 3, no significant change in this
group of patients took place in the end-organ
damage, which has a significant prognostic meaning.
It should be realized that in our study a slightly
modified DI was used. The DI was divided into two
parts, with and without comorbidities. Comorbidities
were defined as end-organ damage presumably
related to treatment, such as recurrent episodes of
infectious diseases, gastro-intestinal bleeding, obesity
and other drug-related complications. As illustrated
in Table 3, nearly 30% of the DI score is derived
from these items. Hypertension was included in our
SLICC=ACR DI caused by the fact that at the start of
our investigation the SLICC=ACR DI was not yet
validated. At present hypertension is excluded as a
clinical sign related to end-organ damage. Looking to
our results and by the group of Rahman et al,33
hypertension can be considered as a very important
clinical sign, caused by the fact that hypertension will
be a risk factor for the development of coronary
artery disease.
In a recent study34 it was demonstrated that the
increase of damage rate was significant during the first
few years after disease onset, and became constant
(stable, without any increase) during a 5 y follow-up.
Our previous results16 demonstrated a significant
correlation between the DI and the disease scoring
systems, suggesting that the disease activity will still
have an impact on the DI. In that respect it is
disputable that the DI really represents the total sum
of accumulated end-organ damage. The present data
(Table 2) suggest that, over the years, the index can
decline as well increase.
At this moment the whole group of patients is still
being followed and in the coming years data related to
the numbers of patients which will eventually enter a
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remission period (free of clinical signs and withdrawal
of all treatment) and the course of end-organ damage
(remaining stable or increasing) will be obtained.
In conclusion, our prospective international co-
operative study of 187 SLE patients with a disease
duration of more than 10 y demonstrates that for the
whole group the disease course is stable with regard to
the two disease activity scoring systems and damage
index. However, in most patients the disease changed
during the past 2 y of observation, illustrated by the
change in prevalence of tiredness, arthritis, malar
rash, migraine, anaemia, leucopenia, proteinuria, and
raised serum creatinine. Overall nearly all patients
needed some form of treatment, illustrated by the fact
that 73% of the patients were still treated with
corticosteroids.
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